ClinicalTrials.gg
RecruitingNCT07302256Updated Jan 14, 2026

A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above

A Phase 1 interventional study of Influenza virus split vaccine (0.7mL/vial) and Influenza virus split vaccine in Influenza, sponsored by Shanghai Institute Of Biological Products. Recruiting at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Shanghai Institute Of Biological Products (part of Sinopharm) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Influenza, Human by Sinopharm — 2 open to participants now, 2 under way, none of them phase 3. Influenza, Human · Sinopharm.

Planned enrollment
15th of 15
120 · median 560
Started
2025
the only one that year
Phase 1
2 of 15
1 open now
Registered
14th of 15
by date

Among the 15 studies in Influenza, Human by Sinopharm, this one is the 15th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 1, and was the 14th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 15 studies in Influenza, Human by Sinopharm are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Sinopharm, or all of them as a file.
02

Study summary

This is a randomized, blinded, controlled phase I clinical trial with a total of 120 participants aged ≥ 60 years. Experimental group: Influenza virus split vaccine (0.7mL/vial), control group 1: Influenza virus split vaccine, control group 2: placebo group. The three groups were recruited at a ratio of 1:1:1, and 40 individuals were randomly vaccinated in each group. Each person was injected with one dose of the vaccine into the deltoid muscle of the upper arm. Participants in each study group are required to undergo laboratory indicator tests before and on the 4th day after vaccination.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Influenza virus split vaccine
  • The elderly
  • Immunogenicity
  • Safety
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 60 years old, gender not limited, and able to provide legal identification;
  • Volunteers voluntarily participate in the study and sign an form;
  • Volunteers have the ability to understand research procedures, use thermometers, scales, and fill out diary cards as required, and can participate in all planned follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • On the day of enrollment, the axillary temperature was ≥ 37.3 ℃;
  • Those who have had influenza in the past 6 months or meet the definition of influenza like cases;
  • Have received any influenza vaccine within the past 12 months or have planned to receive any influenza vaccine during the study period;
  • Allergies to any components of the research vaccine, history of allergic reactions to the use of gentamicin sulfate, history of severe allergies to any vaccine/drug, or history of asthma;
  • Suffering from a serious illness that prevents the completion of the entire study; Within 3 days prior to vaccination, there is an acute illness or an acute exacerbation of a chronic disease;
  • Have used antipyretic or analgesic drugs or anti allergic drugs within 3 days before vaccination;
  • Have received any vaccine within 2 weeks prior to vaccination;
  • Have received therapy or other immunomodulatory drugs within 6 months prior to receiving the experimental vaccine, For example, immunosuppressive doses of , monoclonal antibodies, thymosin, interferon, etc., or planned to receive such treatment within one month after the first dose of vaccination to full immunization, but local medication is allowed;
  • Suffering from congenital or acquired immunodeficiency, (HIV) infection, lymphoma, leukemia, or other diseases;
  • Suffering from serious chronic diseases, serious cardiovascular diseases, such as hypertension that cannot be controlled by drugs, diabetes that cannot be controlled by drugs or has serious complications, liver and kidney diseases, pulmonary edema, malignant tumors, etc;
  • Have received blood or blood related products within the past 6 months;
  • Individuals with progressive neurological disorders, including a history of seizures, epilepsy, encephalopathy, Guillain Barr é syndrome, psychiatric or family history;
  • Have a history of abnormal coagulation function and have been using anticoagulants within 3 weeks before vaccination;
  • Patients with splenectomy, functional splenectomy, splenectomy, or other important organ resection or partial resection;
  • Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
  • Currently or recently planning to participate in other clinical trials;
  • Abnormal laboratory test indicators before vaccination;
  • Researchers determine any situation that is not suitable for clinical trials.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Influenza virus split vaccine, with a specification of 0.7mL/bottle

    Biological: Influenza virus split vaccine (0.7mL/vial)

  • Active comparator
    Control group 1

    Influenza virus split vaccine, with a specification of 0.5mL/bottle

    Biological: Influenza virus split vaccine

  • Placebo comparator
    Control group 2

    Phosphate buffer solution

    Biological: Phosphate buffer solution (PBS)

Interventions

  • BiologicalInfluenza virus split vaccine (0.7mL/vial)

    Influenza virus split vaccine, with a specification of 0.7mL/bottle, containing 60 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each

  • BiologicalInfluenza virus split vaccine

    Influenza virus split vaccine, with a specification of 0.5mL/bottle, containing 15 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each

  • BiologicalPhosphate buffer solution (PBS)

    PBS, with a specification of 0.5mL/bottle.

06

What researchers measure

Primary outcomes

  1. Unsolicited Adverse Events

    Other adverse events that occurred among participants within 0-30 days after vaccination, in addition to the solicited adverse events.

    Time frame: 30 days after vaccination

  2. Solicited Adverse Events (AEs)

    Adverse events defined by the protocol that occurred to the participant during 0-7 days after vaccination.

    Time frame: 7 days after vaccination

  3. Serious Adverse Events (SAE)

    That is serious adverse events, any serious adverse events that occurred to the participant during the study period.

    Time frame: 6 months after vaccination

Secondary outcomes

  1. Seroconversion rate

    30 days after vaccination of all participants with the experimental vaccine or control vaccines, the HI antibody seroconversion rate against any subtype of influenza virus in the experimental vaccine group or the control vaccine groups.

    Time frame: 30 days after vaccination

  2. Ratio of ≥1:40

    30 days after vaccination of all participants with the experimental vaccine or control vaccines, the ratio of HI antibody titers ≥ 1:40 against any subtype of influenza virus in the experimental vaccine group or the control vaccine groups.

    Time frame: 30 days after vaccination

  3. Geometric mean titer (GMT)

    30 days after vaccination of all participants with the experimental vaccine or control vaccines, GMT of HI antibodies against any subtype of influenza virus in the experimental vaccine group or the control vaccine groups.

    Time frame: 30 days after vaccination

  4. Geometric mean increase (GMI)

    30 days after vaccination of all participants with the experimental vaccine or control vaccines, GMI of HI antibodies against any subtype of influenza virus in the experimental vaccine group or the control vaccine groups.

    Time frame: 30 days after vaccination

07

Study locations

1 of 1 sites recruiting
  • Danjiangkou Disease Prevention and Control Center
    Wuhan, Hubei, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2026, 8 months after the start.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 8 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 24, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Aug 31, 2026
CompletionEst.
Aug 31, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07302256
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Dec 16, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Jan 14, 2026

Study contacts

Yang Liu
Contact
liuyang30@sinopharm.com
86-010-65777702
Chaorong Xu
Contact
xuchaorong@sinopharm.com
86-021-62800991
Yeqing Tong
principal investigator · Hubei Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion